The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Shingles Vaccination Not at Goal Levels for U.S. Seniors

Shingles Vaccination Not at Goal Levels for U.S. Seniors

November 28, 2016 • By Madeline Kennedy

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters Health)—Just one in five people over age 60 in the U.S. have been vaccinated against a painful eruption of herpes zoster (shingles), despite recommendations that all of them should get the shot.

You Might Also Like
  • Tofacitinib After Live Shingles Vaccination Does Not Impair Immunogenicity
  • GlaxoSmithKline’s Shingles Vaccine Gets Approval in Canada
  • Shingles, Chickenpox Hospitalizations Higher for Patients on Anti-TNF Drugs

It’s estimated that among people over age 50, one in three will eventually develop shingles. After age 80, half of adults have had shingles.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“The rash usually heals within two to four weeks; however, some people develop ongoing nerve pain which can last for months or even years,” says lead author Dongmu Zhang of Merck and Co., Inc., a New Jersey-based pharmaceutical company that makes a shingles vaccine.

“Vaccination of appropriate adults may help to prevent or attenuate herpes zoster,” Zhang says by email, adding that the Center for Disease Control and Prevention recommends it for all adults over 60.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The vaccine is also approved for people aged 50–59, though guidelines stop short of recommending it for that age group. The federal government’s Healthy People 2020 initiative set a goal of having 30 percent of people over 60 vaccinated by 2020, Zhang’s team writes in the American Journal of Preventive Medicine, online Oct. 26.¹

To determine how many older adults are getting the vaccine, the study team used data from two healthcare databases, one including nearly 7 million adults over age 60 and another with 7 million people between 50–60. Researchers looked at how many of them received the herpes zoster vaccine between 2007 and 2013.

They also looked at factors that might affect whether or not people got the vaccine, including age, sex, geographic area, health insurance type and whether or not the person had a compromised immune system.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The team found that by 2013, less than 2% of 50–60 year olds, 24% of adults between 60 and 64 and 15% of adults over 65 had received the herpes zoster vaccine.

The vaccine was first approved in 2006, and the number of people getting vaccinated each year went up between 2007 and 2013, researchers note.

Women and people with normal immune systems were more likely to receive the vaccine, as were people who visited doctors and pharmacies for regular medical care more often. But people who visited emergency departments and had inpatient hospital stays were less likely to get the vaccine.

People who got the flu vaccine were also more likely than those who didn’t to have had the herpes zoster vaccine.

Zhang’s team urges doctors to use routine health encounters like a visit for flu vaccination as opportunities to also educate people about the shingles vaccine and urge them to get it.

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: CDC, elderly, herpes zoster, shingles, vaccination, vaccine

You Might Also Like:
  • Tofacitinib After Live Shingles Vaccination Does Not Impair Immunogenicity
  • GlaxoSmithKline’s Shingles Vaccine Gets Approval in Canada
  • Shingles, Chickenpox Hospitalizations Higher for Patients on Anti-TNF Drugs
  • GSK Wins U.S. Shingles Vaccine Approval, U.K. Nod for Gene Therapy

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)